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KAREN ROTHENBERG’S (NOT SO) 
SECRET ROLES AND 
CONTRIBUTIONS  
AT THE U.S. NATIONAL 
INSTITUTES OF HEALTH 
BENJAMIN E. BERKMAN, J.D., M.P.H.1,2, LAWRENCE C. BRODY, PH.D.2, 
FRANCIS S. COLLINS, M.D., PH.D.2,3,  AND ERIC D. GREEN, M.D., PH.D.2* 
I. INTRODUCTION 
As the metaphorical ‘center of the biomedical research universe,’ the U.S. 
National Institutes of Health (NIH) regularly attracts the best and brightest minds 
to help the agency pursue its mission – that is, “to seek fundamental knowledge 
about the nature and behavior of living systems and the application of that 
knowledge to enhance health, lengthen life, and reduce illness and disability.” 
Achieving that mission in a socially responsible fashion depends on establishing 
and maintaining a strong ethical and legal framework, something of profound 
interest and concern to Professor Karen Rothenberg throughout her lengthy 
career as a prominent legal scholar. It was, therefore, perhaps inevitable that NIH 
and Karen would connect in highly productive and meaningful ways.  
Karen’s interactions involved distinct parts of the NIH – specifically, the 
National Human Genome Research Institute (NHGRI) and the Clinical Center’s 
Department of Bioethics – and occurred intermittently over two decades, being 
most intense during two periods. The first of these occurred in the 1990s, during 
which Karen served as a valued ad hoc advisor to a then-adolescent NHGRI. At 
that time, Francis Collins was the NHGRI Director, the field of genomics was 
young and growing rapidly, and the Human Genome Project (HGP) was in full 
swing. The second of these involved a more formal role from 2011 to 2015, 
during which Karen served as a Special Advisor to the NHGRI Director (Eric 
Green) and was also an Adjunct Faculty Member in the Clinical Center’s 
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Department of Bioethics. During both of these stints, Karen’s ability to straddle 
the academic and policy divide allowed her to contribute as an advocate, advisor, 
educator, scholar, and mentor. 
II. ADVOCATE 
Until the HGP came along, few if any scientific fields had sought to 
anticipate the ethical, legal, and social consequences of their work, much less 
analyze the societal implications and recommend legislative action – all long 
before major advances from that work were realized. But starting in 1990, that is 
precisely what the National Center for Human Genome Research (later renamed 
NHGRI) did. At that time, an important issue emerged that, if not dealt with 
effectively, could limit the societal benefit of genomics research: there needed to 
be an effective way to prevent genetic discrimination.  
To be successful, this effort required bold leadership. Karen’s vision, 
passion, and deep expertise made her ideal for this role. As the Marjorie Cook 
Professor of Law and Director of the Law and Health Care Program at the 
University of Maryland Law School, she had the legal gravitas and personal 
commitment to turn policy goals into concrete actions. As the National Action 
Plan on Breast Cancer (NAPBC) came alongside as a natural partner in this 
policy effort, Karen was appointed to NAPBC’s organizing body and quickly 
became a leading voice at workshops and public discussions focused on avoiding 
genetic discrimination. This led to her co-authoring a landmark 1995 Science 
paper on genetic information and health insurance1 and subsequently a 1997 
Science paper that provided specific recommendations to avoid workplace 
discrimination on the basis of genetics.2 
Those two articles became the foundation for everything that followed. 
Though none of us thought that it would take more than a decade for effective 
federal legislation to become law, we all celebrated in May 2008 when the 
Genetic Information Nondiscrimination Act (GINA) was signed into law. Along 
with an amazing team of scientists, advocates, legal scholars, and policy experts, 
Karen had helped birth legislation with consequences so significant and profound 
that Senator Edward Kennedy called GINA “the first major new civil rights bill 
of the new century”.3 
 
 1. Kathy L. Hudson et al., Genetic Discrimination and Health Insurance: An Urgent Need for 
Reform, 270 SCIENCE 391 (1995). 
 2. Karen H. Rothenberg, et al., Genetic Information and the Workplace: Legislative Approaches 
and Policy Changes, 275 SCIENCE 1755 (1997). 
 3. Kathy L. Hudson et al., Keeping Pace with the Times – The Genetic Information 
Nondiscrimination Act of 2008, 358 NEW ENGLAND J. MED. 2661 (2008). 
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III. ADVISOR 
Upon his appointment as NHGRI Director in 2009, Eric Green immediately 
accelerated an ongoing round of strategic planning at the Institute. At several key 
meetings related to the crafting of NHGRI’s 2011 strategic plan,4 Karen 
contributed important and thoughtful input to intense discussions about the future 
of NHGRI’s then-mature Ethical, Legal, and Social Implications (ELSI) 
Research Program. Those contributions led to Karen playing a larger role 
advising the new NHGRI Director on the reorganization and ‘modernization’ of 
the Institute. Karen’s experience as the Dean of a major law school brought a 
valued perspective, along with remarkable wisdom and sound judgment, to her 
role as a Special Advisor.  
While Karen’s advice related to multiple parts of NHGRI, her efforts were 
most focused on the Institute’s Extramural Research Program (ERP). The ERP 
oversees the funding of researchers outside of NIH and is responsible for roughly 
three-quarters of the funds allocated to NHGRI by the U.S. Congress. For many 
years, NHGRI’s ERP was laser-focused on the HGP, requiring a relatively 
simple organizational structure. By the time of Karen’s arrival as a Special 
Advisor (nearly a decade past the completion of the HGP), the breadth of 
scientific areas covered by the NHGRI ERP had grown substantially. Managing 
such a diverse program required a different organizational model. Ultimately, a 
new configuration emerged that converted the NHGRI ERP from a single large 
entity into a thematically defined four-division structure, one that then required 
the appointment of four new division directors. Needless to say, this involved a 
substantial amount of ‘change management,’ something that was greatly aided 
by Karen’s sage advice and counsel.  
Karen’s experience and expertise were particularly well-suited for helping 
with one component of NHGRI’s ERP, the ELSI Research Program (which by 
congressional mandate, is associated with 5% of the Institute’s research budget). 
The Institute’s reorganization in 2012 provided the opportunity to elevate the 
ELSI Research Program by making it the centerpiece of a new division (the 
Division of Genomics and Society). Karen urged that the new Division embrace 
a larger scope of activities beyond the ELSI Research Program, including a major 
‘ELSI consultative role5 and opportunities for its staff to participate in scholarly 
and outreach activities. With these added responsibilities, Karen recognized that 
the Division would need ongoing advice over time. Towards that end, she helped 
to establish a standing advisory body, the Genomics and Society Working Group; 
the work of this group ensured that appropriate attention is paid to ELSI research 
 
 4. Eric D. Green et al., Charting a Course for Genomic Medicine from Base Pairs to Bedside, 470 
NATURE 204 (2011). 
 5. Jean E. McEwen et al., The Ethical, Legal, and Social Implications Program of the National 
Human Genome Research Institute: Reflections on an Ongoing Experiment, 15 ANNUAL REV. OF 
GENOMICS AND HUM. GENET. 481 (2014).  
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within NHGRI’s ever-growing research portfolio. Karen’s valued input also 
aided the Division of Genomics and Society’s first permanent Director, 
Lawrence Brody. Finally, Karen advocated for the Division to take a holistic 
approach to its work. While ethical, legal, and social research can easily (and 
often does) occupy three unconnected academic silos, Karen urged NHGRI to 
join these silos and develop approaches for scholars in each of these areas to 
work together. This highly collaborative approach to ELSI research represents a 
lasting contribution of Karen’s advice. 
IV. EDUCATOR 
The University of Maryland Law School is renowned for its health law 
program, but Karen was inspired to move beyond the normal law school 
pedagogic focus on abstract legal theory by providing law students with an 
opportunity to gain real-world experience in health policy at NHGRI. 
Specifically, she developed the idea for an intensive workshop where students 
would research and analyze a range of ethical, legal, and policy questions raised 
by the increasing prevalence of human genome sequencing in research. Do 
investigators have an ethical or legal duty to look for secondary findings? Does 
the CLIA regulatory regime make sense in an era of genomic research? How 
should institutional policies be structured to grapple with the challenges inherent 
in obtaining informed consent to sequence an individual’s genome? How could 
we strengthen laws protecting people against genetic discrimination? In close 
consultation with NHGRI scientists and policy-makers, the students developed 
meaningful insight about these (and other) real ethical and policy problems that 
NHGRI was actively confronting. The intensive NHGRI policy experience was 
so successful that Karen then created an ongoing NHGRI externship course 
(which just completed its fourth year) in which law students are embedded in 
various NHGRI groups for a semester. These innovative educational experiences 
have been quite successful, but they were only possible because of Karen’s 
unique position straddling the academic and policy worlds.  
As another example of Karen’s creativity in expanding pedagogic 
boundaries, she turned her passion for theater into a tool for teaching bioethics. 
In collaboration with Lynn Bush (Columbia University), Karen recognized that 
many of the ethical issues raised by genomics research and genomic medicine 
have a substantial emotional component and require more than just detached 
normative analysis. The duo wrote and staged innovative plays designed to 
immerse an audience into the ethical debate, staging these plays at academic 
conferences and local theaters. She even organized a conference at NHGRI 
where playwrights were exposed to scientific and bioethical issues to serve as 
inspiration in their own work. Karen and Lynn eventually wrote a book about 
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this experience, which hopefully will be a useful tool as the scientific world 
continues to grapple with difficult issues inherent to genomic advances.6 
V. SCHOLAR AND MENTOR 
As an Adjunct Faculty Member in the NIH Clinical Center’s Department 
of Bioethics, Karen contributed her wisdom and expertise as a scholar in 
residence and mentor. Through active discussion and collaboration, she helped 
to sharpen her colleagues’ arguments. For example, Karen co-authored an article 
with Department of Bioethics colleagues analyzing the liability issues raised by 
the return genomic incidental findings to research participants.7 Published by the 
highly ranked Georgetown Law Journal, this paper provided a framework for 
courts to grapple with the potential onslaught of cases that inconsistent return of 
results policies would likely provoke. 
Through disagreement and combative collegiality, Karen’s advice and 
critique of bioethics projects proved invaluable to strengthening colleagues’ 
scholarly work. As an example, one of us (BEB) has written extensively with 
skepticism about the idea that people should have a strong right not to know 
medically important genomic information about themselves.8 Karen 
emphatically disagreed, arguing that individuals should be able to refuse 
information about their genome, particularly information resulting from genetic 
tests. The ensuing debates were instrumental for identifying and addressing 
weaknesses in this controversial argument. While still on different sides of the 
academic debate to this day, Karen’s unfettered willingness to engage in high-
level scholarly debate were undeniably helpful. 
VI. A LEGACY OF VALUED CONTRIBUTIONS 
Karen is a noted health law scholar and leader in the ELSI research 
community, but her career has also included a less well-known but equally 
important public service role as an advisor to NHGRI and NIH. In this role, 
Karen has effectively drawn on her experience in legal academia to provide 
invaluable insight to the emerging fields of genomics and genomic medicine. 
Karen’s distinct combination of enthusiasm and wisdom helped to ensure that 
genomics research was built upon a foundation of ethical and legal scholarship. 
Her work continues to influence the field to this day. 
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